On June 2, 2014 Biocept, Inc. (NASDAQ:BIOC) a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), announced the launch of its estrogen receptor (ER) status testing on CTCs that will be performed at the Company’s CLIA-certified and CAP-accredited laboratory. Biocept Inc (NASDAQ:BIOC) weekly performance is 21.44%. On last trading day company shares ended up $5.38. Biocept Inc (NASDAQ:BIOC) distance from 50-day simple moving average (SMA50) is -1.07%.
On May 19, Vision-Sciences, Inc. (NASDAQ:VSCI) a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, announced the launch of its next generation video bronchoscope and EndoSheath technology. The new BRS-5100 video bronchoscope was unveiled at the annual ATS (American Thoracic Society) Meeting in San Diego, California on May 18 — 20, 2014. Vision-Sciences, Inc. (NASDAQ:VSCI) shares fell -5.11% in last trading session and ended the day on $1.11. Gross Margin is 30.10% and its return on assets is -66.20%. Vision-Sciences, Inc. (NASDAQ:VSCI) quarterly performance is -32.72%.
On June 2, Equities researchers at Roth Capital started coverage on shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) in a research report issued on Thursday. The firm set a “buy” rating and a $28.00 price target on the stock. Roth Capital’s price target indicates a potential upside of 216.74% from the company’s current price. Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares moved down -5.12% in last trading session and was closed at $8.34, while trading in range of $8.20-$8.81. Concert Pharmaceuticals Inc (NASDAQ:CNCE) year to date (YTD) performance is -41.18%.
On May 29, 2014, Retrophin Inc (NASDAQ:RTRX) entered into a Note Purchase Agreement with the investors identified therein, relating to a private placement by the Company of up to $46,000,000 aggregate principal amount of its 4.50% Senior Convertible Notes due 2019, which are convertible into shares of the Company’s common stock, par value $0.0001 per share at an initial conversion price of $17.41 per share of Common Stock. The transactions contemplated by the Note Purchase Agreement were not a “public offering” as defined in Section 4(2) of the Securities Act of 1933, as amended, and met the requirements to qualify for exemption under Regulation D promulgated under the Securities Act (“Regulation D”). Retrophin Inc (NASDAQ:RTRX) ended the last trading day at $11.17. Company weekly volatility is calculated as 11.24% and price to cash ratio as 46.68. Retrophin Inc (NASDAQ:RTRX) showed a negative weekly performance of -13.28%.
Hemp, Inc. (OTCMKTS:HEMP) announced its support of the 5th Annual Hemp History Week from June 2 through June 8, 2014. The week long awareness campaign, themed “It’s Time to Grow”, features thousands of events across the country (including movie screenings of “Bringing it Home” and “The Emperor of Hemp”) in an effort to educate and raise awareness regarding the environmental and nutritional benefits of Industrial Hemp and hemp-based products. HEMP, INC. (OTCMKTS:HEMP) On last trading day company shares ended up $0.0583 .
Leave a Reply